Original Article httpdxdoiorg103349ymj201354171 pISSN 05135796 eISSN 19762437 Yonsei Med J 5417180 2013 Prevalence Incidence Factor Concentrate Usage Trends Hemophiliacs Taiwan TsuChiang Tu12 WenShyong Liou34 TsuiYun Chou5 TsungKun Lin2 ChuanFang Lee2 JyeDaa Chen2 ThauMing Cham1 MeiIng Chung1 1School Pharmacy Kaohsiung Medical University Kaohsiung 2Department Pharmacy Practice TriService General Hospital Taipei 3Department Pharmacy Taichung Veterans General Hospital Taichung 4College Pharmacy China Medical University Taichung 5The Hemophilia Care Research Center TriService General Hospital Taipei Taiwan Received November 22 2011 Revised March 1 2012 Accepted March 9 2012 Corresponding author Dr MeiIng Chung School Pharmacy Kaohsiung Medical University No 100 ShiChuan 1st Road Kaohsiung 807 Taiwan Tel 88673121101 2672 Fax 88673210683 Email meinchkmuedutw The authors financial conflicts Purpose Hemophilia A B HA HB common Xlinked inherit ed bleeding disorders The introduction factor concentrates allowed trol lifelong chronic disease However studies published garding epidemiology hemophilia Taiwan Our aim determine prevalence incidence mortality rate trends use factor centrates individuals hemophilia Taiwan Materials Methods A retrospective study conducted National Health Insurance Research Database 1997 2007 Results We identified 988 males hemo philia HA HB ratio54 1 The mean prevalence 100000 males 6701 HA 1201 HB The estimated mean annual incidence live male birth 1 10752 HA 1 47619 HB Standardized mortality ratios males hemophilia severities severe hemophilia 13 21 fold higher general male population respectively Mean factor VIII FVIII factor IX FIX usage 1500304029 0312600904 interna tional units IUs capita respectively Mean FVIII FIX usage patient hemophilia severities severe hemophilia 4402711532 7234117298 respectively 4940713015 7436918411 IUs person HA HB respectively Conclusion Our data revealed epidemiologic factor concentrate usage trends males hemophilia Taiwan highlighting need improvements mandatory National Health Insurance registry A bet terdesigned patientcentered registry enable detailed patient information collection analysis improving subsequent care Key Words Hemophilia prevalence incidence factor VIII factor IX Taiwan Copyright Yonsei University College Medicine 2013 This Open Access article distributed terms Creative Commons Attribution Non Commercial License httpcreativecommonsorg licensesbync30 permits unrestricted non commercial use distribution reproduction medium provided original work properly cited INTRODUCTION Hemophilia A HA B HB common xlinked inherited bleeding disorders resulting clotting factor VIII FVIII factor IX FIX deficien Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 71 TsuChiang Tu et al cy respectively The disease classified mild moderate severe based degree deficiency coagula tion factor1 Because hereditary pattern hemophil ia patients male females disease carriers The introduction replacement therapy plasmaderived clotting factor concentrates ear ly 1970s substantially reduced bleeding episodes pre vented musculoskeletal damage improved orthopedic outcomes quality life patients hemophilia2 Even patients severe hemophilia entail creased life expectancy overall life expectancy pa tients hemophilia approaching general male population35 Following recommended prophylactic treatment home therapy comprehensive care enables hemophiliacs enjoy better general state health engage daily activities social events work earning education68 In March 1995 Taiwan launched mandatory National Health Insurance NHI program integrated exist ing healthinsurance programs labor government employee farmer insurance By end year effect NHI extended coverage 92 total population By end 2004 coverage reached approximately 99 population nearly 23 million beneficiaries enrolled NHI9 The NHI singlepayer compulsory social health surance program organized government oper ated Bureau National Health Insurance BNHI The primarily funded premiums collectively paid insured employers central local gov ernments In beginnings feeforservice predomi nantly accepted public private healthcare pro viders The NHI program extends patients freedom choice seeking medical care utilizes costshar ing strategies reduce potentially unnecessary services Facing spiraling growth medical costs payment sys tem NHI changed feeforservice global budget 2002 order healthcare costs trol impeding quality care To better manage medical expenditures enhance professional autono medical providers payment methods introduced payforperformance diagnosis related groups resourcebased relative value scale recent years10 Hemophilia classified catastrophic illness NHI program implemented ex empting patients copayment assuring pa tients able obtain treatment factor concentrates However studies published epi demiologic characteristics hemophiliacs Taiwan Fur thermore examination trends factor concentrate use critical planning reasonable budget improving care offered patients hemophilia BNHI The primary aim research determine prevalence incidence mortality rate patients hemophilia Taiwan The second aim assess trends use FVIII FIX international units IUs capita IUs person HA HB MATERIALS AND METHODS Since implementing NHI BNHI cooperated National Health Research Institute nonprofit research organization founded sponsored Department Health establish National Health Insurance Research Databases NHIRDs The national claim data available 1997 A retrospective study conducted ing data NHIRDs period January 1997 December 2007 Epidemiologic study The study subjects identified 19972007 Registries Catastrophic Illness patient files cluded following data scrambled identifier gender di agnosis date birth date hospital application disease severity date death Each patient identified single unique code retained pa tient left later reenrolled assuring patient evaluated study Prevalence 100000 males year defined total number identified male hemophiliacs gen eral male population divided total number general male population relevant year Incidence 100000 live male births year defined num ber males hemophilia general male new borns divided total number general male new borns relevant year The crude mortality rate expressed number deaths males hemophilia cohort 100000 personyears risk The agestandardized mortali ty rate 100000 males based World Health Organization WHO standardization weight factors11 Standardized mortality ratio SMR computed 72 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 Factor Usage Trends Hemophiliacs Taiwan compare mortality rate entire Taiwan male population ratio observedtoexpected mor tality The number expected deaths calculated cohort multiplying number personyears followup 5year age categories 04 598084 85 89 89 years corresponding agespecific mor tality rates general Taiwan male population sum ming results age groups Agespecific mortality rates general Taiwan male population 2002 calculate SMR study population fol lowed 1997 2007 The general male popula tion statistics mortality rate data obtained Taiwan Ministry Interior Department Health respectively1213 Factor usage trend study To analyze trends factor concentrate usage data rived following original claim data ambulatory care expenditures visits CD inpatient expenditures admis sions DD details ambulatory care orders OO details inpatient orders DO registry drug prescriptions DRUG Insurance claims data consisted date visits hospitalization patient demographics scrambled identifi er gender date birth medical facility visited ICD9 CM diagnosis codes procedure codes special procedures details prescription drug use DRUGs detailed drug code drug content content unit dos age form FVIII FIX usage IUs capita defined total number IUs consumed divided total population relevant year FVIII FIX usage patient IUs son hemophilia A PWHA person hemophilia B PWHB defined total number IUs consumed divided HA HB subjects relevant year similar reported Stonebraker et al14 Statistical analysis Descriptive statistics reported mean stan dard deviation distribution data preva lence incidence factor usage Regression analyses performed yearly basis determine association factor usage strength association assessed correlation coefficient R slope regres sion line S time provided measure annual trend Ninetyfive percent confidence intervals calcu lated mortality rate based Poissons distribution All statistical analyses conducted STATA software version 110 StataCorp LP Lakeway TX USA15 RESULTS General population characteristics Fig 1 flow chart enrollment subjects included study There 988 patients hemophilia 833 patients identified HA 155 patients HB Table 1 shows characteristics pa tients comprises total 9951 personyears obser vation In population ratio HA HB 54 1 Hemophilia characterized severe 574 patients 581 moderate 138 patients 140 mild 276 279 individuals Fiftyfive patients died prior conclusion study 2007 933 patients living Of surviving patients 279 299 18 years age younger 654 701 older 18 years For surviving patients HA mean age 297171 years surviving patients HB 272177 years Consecutive data male hemophiliacs newborns deceased patients shown Table 2 The number 19972007 registration files catastrophic illness patients n13285657 Exclude deficiency clotting factors diagnosis patients n13265011 19972007 registration files deficiency clotting factors n20646 Patientcentered unique identifier review exclude duplication n19245 Registration files deficiency clotting factor patients n1401 Exclude factor VIII factor IX disorder patients n360 Registration files factor VIII factor IX disorder patients n1041 Exclude factor VIII factor IX disorder female patients n53 Registration files factor VIII factor IX disorder male patients n988 Registration files Haemophilia B male patients n155 Registration files Haemophilia A male patients n833 Fig 1 Flow chart inclusion Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 73 TsuChiang Tu et al Table 1 General Characteristics According Type Hemophilia Patients Personyears Patients severity Severe Moderate Mild Patient status Alive Deceased Age description Alive Mean age Median age Age categories Adolescents 018 yrs Adults 1965 yrs Adults 65 yrs Deceased status Mean age death Median age death HA hemophilia A HB hemophilia B HA 833 8399 480 576 110 132 243 292 784 941 49 59 HB 155 1552 94 606 28 181 33 213 149 961 6 39 Hemophiliacs HAHB 988 9951 574 581 138 140 276 279 933 944 55 56 297171 282 01902 272177 237 08901 293172 276 01902 229 292 534 681 21 27 50 336 94 638 5 26 279 299 242 673 412 28 468195 461 30878 410214 463 41681 462196 461 30878 Table 2 Consecutive Data Male Hemophiliacs Newborns Deceased Patients Hemophilia Study Pe riod 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Patients HA HB Hemophiliacs HAHB Newborns HA HB Hemophiliacs HAHB Deceased HA HB Hemophiliacs HAHB HA hemophilia A HB hemophilia B 728 130 858 16 2 18 3 0 3 735 132 867 10 2 12 4 0 4 749 134 883 18 2 20 7 1 8 751 140 891 9 7 16 0 0 0 762 141 903 11 1 12 5 2 7 767 140 907 10 1 11 7 0 7 774 143 917 14 3 17 4 0 4 780 145 925 10 2 12 6 1 7 785 147 932 11 3 14 9 0 9 784 149 933 8 2 10 4 0 4 784 151 935 4 2 6 0 2 2 hemophiliacs increased 858 935 end 2007 Also 148 male newborn patients diagnosed HA n121 HB n27 study period The number deceased patients HA n49 HB n6 included deceased patients 19972007 birth cohort Epidemiologic profile The annual prevalence HA 100000 males increased 65 1997 68 2007 The annual prevalence HB 100000 males increased 12 1997 13 2007 The annual prevalence HAHB 100000 males increased 77 1997 81 2007 The mean annual prevalence 100000 males 6701 HA 1201 HB 7901 HAHB Fig 2 shows mean incidence hemophilia 100000 live male births year 5year intervals 1978 1982 19831987 19881992 19931997 19982002 20032007 1978 2007 The mean incidence consecutive periods ranged 86 103 9307 HA 17 29 2105 HB 104 126 11408 HAHB The estimated average cidence live male births year 1 10752 HA 1 47619 HB 1 8772 HAHB The mortality rate 100000 personyears SMR 74 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 Factor Usage Trends Hemophiliacs Taiwan based disease type hemophilia shown Table 3 The overall crude mortality rate agestandardized mor tality rate individuals hemophilia 5740 95 CI 52806229 6933 95 CI 64247466 respectively As expected crude mortality rate age standardized mortality rates somewhat higher pa tients severe hemophilia Among general male population Taiwan overall SMR 14 individ uals HA 13 individuals hemophilia For patients severe hemophilia SMR times higher general male population Factor usage Fig 3 summarizes factor usage data inclusion The timese ries results FVIII FIX usage IUs capita period 19972007 presented Table 4 FVIII age IUs capita increased time 09583 1997 22793 2007 24fold increase Additionally FVIII usage IUs capita plasmaderived concen trates showed 82 reduction 01686 2007 begin ning 1997 At time FVIII recombinant concen trate use increased 21104 2007 92fold increase 1999 2007 FIX usage IUs capita increased time 02306 1997 04644 2007 2fold crease Furthermore FIX usage IUs capita plasma derived concentrates decreased 40 01374 2007 FIX recombinant concentrate use 03270 2007 52fold increase 2002 2007 The mean FVIII age 1500304029 showed annual growth HAHB HA HB 140 120 100 80 60 40 20 0 19781982 19831987 19881992 19931997 19982002 20032007 Fig 2 Mean incidence 100000 male livebirths year 5 years terval 19782007 period HA hemophilia A HB hemophilia B 19972007 outpatient visit data 19972007 inpatient visit data Extract ICD9CM diagnosis codes coagulation defects deficiency clotting factors data Linkage factor VIII factor IX drug code registry file drug prescriptions Extract factor VIII factor IX prescription drug use data Factor IX prescription data n19365 Factor VIII prescription data n113310 Fig 3 Flow chart inclusion factor usage data Table 3 Crude Standardized Mortality Rates Per 100000 Males Per Year Rate Ratios 19972007 Period HA HB Hemophiliacs HAHB Crude mortality rate 95 CI All severities Severe Moderate Mild Agestandardized mortality rate 95 CI All severities Severe Moderate Mild Standardized mortality ratio All severities Severe Moderate Mild 5944 54726437 6465 59716978 5945 54726438 5485 50405969 6844 63377372 7389 68677943 6953 6443 7486 4431 40274862 14 1019 21 1727 14 1019 08 0511 HA hemophilia A HB hemophilia B CI confidence interval 5053 46195510 6313 58276822 4464 40564894 1377 11591630 6252 57706760 5722 52616208 3775 34084181 1345 11321598 10 0814 20 1626 10 0814 03 0106 5740 52806229 6391 59046905 5201 47635667 5043 46095500 6933 64247466 7190 66747735 5876 54146375 5213 47725677 13 0919 21 1727 14 1019 07 0410 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 75 TsuChiang Tu et al Table 4 Factor VIII Factor IX Usage IUs Per Capita Study Period 1997 1998 1999 2000 2001 1281 2002 2003 R 14083 15675 16058 18044 20147 22793 15003 04029 01177 09322 2007 Mean 2005 2004 2006 SD S 1228 09583 11023 09212 04592 05908 05735 04423 03677 02702 01783 01686 05484 03204 00903 08588 03326 07688 06902 08348 11252 12381 15341 18364 21107 11634 0578 02068 09541 02306 02344 01437 02741 02892 03337 0329 03567 03778 04045 04644 03126 00904 00251 08274 02306 02344 01437 02741 0285 02705 01927 01705 01602 01316 01374 02028 00583 00102 02664 00041 00632 01363 01863 02176 02729 0327 01725 01139 00525 09895 09583 11023 12538 Factor VIII Factor VIII plasma derived Factor VIII recombinant Factor IX Factor IX plasma derived Factor IX recombinant IUs international units SDs standard deviation Slope regression line Correlation coefficient Table 5 Factor VIII Factor IX Usage Per Patient IUs Per PWHA PWHB Study Period Patients hemophilia PWHA Severe Moderate Mild PWHB Severe Moderate Mild 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Mean SD S R 28622 47992 11161 1117 38573 58913 15240 5000 32887 55090 9913 1116 38934 59146 17596 4430 36981 62449 9683 1499 23684 37658 5996 503 36427 61754 9678 1428 43609 68066 12982 1969 37665 41350 63494 67984 9373 14051 1112 2327 45948 53677 68866 82800 19518 11167 3344 3063 45780 75923 13253 1185 52002 79330 14741 1359 46710 76288 16888 1142 55821 79945 25511 2000 52339 84565 17873 2241 58520 86020 27931 2867 58788 66747 44027 93992 106222 72341 23708 28651 14930 2498 1696 1578 62104 70603 49407 93241 104078 74369 24870 30741 18754 2227 5030 2890 11532 17298 6378 536 13015 18411 7714 1475 3354 0923 09272 5042 07434 1686 02505 92 07857 3526 07627 4923 05192 1752 00051 32 SD standard deviation PWHA person hemophilia A PWHB person hemophilia B Slope regression line Correlation coefficient 01177 IUs capita year mean FIX usage 0312600904 IUs capita showed annual growth 00251 IUs capita year The timeseries results FVIII FIX usage patient IUs PWHA PWHB presented Table 5 FVIII usage patient IUs PWHA showed 23fold crease 1997 28622 2007 66747 Similarly FIX usage patient IUs PWHB increased 18 fold tween 1999 23684 2007 70603 Moreover additional severities analysis revealed 22 increase FVIII usage patient IUs PWHA 1997 47992 2007 106222 patients severe HA 26fold increase moderate HA 11161 1997 28651 2007 15fold increase mild HA 1117 1997 1696 2007 The mean FVIII usage pa tient severe HA 7234117298 annual growth 5042 IUs PWHA 104078 The mean FIX usage patient severe HB 7436918411 annual growth 4923 IUs PWHB In moderate HB FIX age patient IUs PWHB showed dramatic 51 fold increase 5996 1999 30741 2007 Nota bly mild HB FIX usage patient IUs PWHB showed difference years 1997 2007 usage drop period DISCUSSION This study report populationbased data mophilia Taiwan The objectives study determine baseline epidemiologic profiles factor centrate usage trends hemophiliacs Taiwan For patients severe HB FIX usage patient IUs PWHB increased 28 fold 1999 37658 2007 Epidemiologic profile The mean prevalence HA severities research 76 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 Factor Usage Trends Hemophiliacs Taiwan database 6701 100000 males Similar results obtained Japan 5905 Korea 530416 Hong Kong 6417 slightly lower reported Singapore 780216 Our results demonstrated lower prevalence reported Netherlands 11718 Italy 10019 United Kingdom 21420 Canada 14321 United States 10522 The mean prevalence HB severities 1201 100000 males Simi lar results obtained Japan 130123 Sin gapore 110123 slightly higher sults reported Korea 100223 lower results Italy 2019 United Kingdom 4520 Canada 3324 Recently Stonebraker et al16 reported prevalenc es hemophilia 106 countries 1998 2006 The prevalence HA 100000 males according World Bank classification high income USD 11116 Organization Economic Cooperation Development OECD nonOECD countries 128 60 8440 respectively Second prevalence HA 12915 Canada 9822 Netherlands 16829 United Kingdom Third prevalences HA Asian OECD nonOECD counties Ja pan Korea Singapore lower average prevalence obviously lower fre quently reported literature pertaining Caucasians Few studies222526 reported raceethnicity differ ences hemophiliac epidemiology The incidence mophilia Chinese reported slightly lower Caucasians25 Soucie et al22 reported ageadjusted prevalence hemophiliacs 132 100000 males white Americans 110 Afri canAmericans 115 Hispanic males 43 AsianPacific Islanders United States However results Soucie et al22 interpreted cau tion based small number cases variation rates 0153 100000 males AsianPacific Islanders different states Additionally Chen et al26 reported prevalence intron 22 inversion Chinese patients severe HA reported previous stud ies Caucasian populations based genetic analysis The forgoing literature revealed interesting differences hemophilia raceethnicity demonstrating need concern variations Compared general male population Taiwan SMR individuals hemophilia se vere hemophilia 13 2fold higher general male population Similar results obtained previous studies527 reported mortality rate causes death hemophiliacs period posed greatest risk bloodborne virus transmission Plug et al5 reported individuals hemophilia Netherlands 1992 2001 SMRs hu man immunodeficiency virus HIVpositive negative individuals 23 17 fold higher general male population respectively rates creased severe hemophilia 51 28fold respectively In study hemophilia Italy Tagliaferri et al27 reported SMR hemophiliacs creased 20 years 1990 1999 SMR 11 years 2000 2007 compared gen eral male population A similar shift SMR seen individuals severe hemophilia decreasing 41 1990 1999 33 2000 2007 Acquired immunodeficiency syndrome AIDS resulting HIV liver failure caused hepatitis C virus HCV contaminated concentrates produced 1985 The important cause death 1970s early 1980s replaced AIDS leading cause death late 1980s early 1990s mophiliacs28 During 10 years effect HCV related endstage liver disease mortality dom inant5 Unfortunately study NHIRD provide access databases mortality data required study causes death severity age differences conduct outcome assessments Ac cording data retrievable Taiwans Centers Disease Control 53 HIVpositive hemophilia cases reported date All HIVpositive individuals diagnosed 1984 1997 45 cases diagnosed 199029 This related use contaminated blood concentrates hemophiliacs 1985 Taiwan The available data showed 31 affected hemophiliacs died 1984 200230 2003200731 It difficult elucidate HIVposi tive hemophiliacs contributed mortality rate results Thus studies address specific causes death relevant issues Factor usage Another objective study assess FVIII FIX usage trends Taiwan The results study indi cated increasing trend FVIII FIX concentrate use Taiwan Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 77 TsuChiang Tu et al Results FVIII usage 1500304029 IUs capita FVIII usage patient 4402711532 IUs PWHA annual increase consistent previous port FVIII usage IUs capita IUs PWHA increased time countries14 Additionally FVIII usage IUs capita FVIII usage patient IUs PWHA similar mean results reported high income nonOECD countries 1400012381 47105 60130 Compared Asian OECD nonOECD counties results mean FVIII usage IUs capita similar reported Korea 1286404170 Hong Kong 1465807319 slightly lower Japan 19511 02272 considerably higher Singapore 0612802129 The mean FVIII usage patient IUs PWHA results similar reported Korea 4704814899 slightly lower reported Japan 667976421 considerably higher reported Singapore 14940632214 In general goals factor replacement therapy prevent joint nonjoint bleeding retard onset andor delay progression disease Factor sumption drug utilization patterns influenced mul tiple variables replacement therapy patterns dose regimen protocol reimbursement policy healthcare ser vice type Briefly prophylaxis recommended opti mal therapy patients hemophilia World Feder ation Hemophilia WHO32 Prophylactic therapies widely adopted Europe North America Japan3334 recently initiated Taiwan In context treatment strategies healthcare policies vary widely countries greatly impact factor usage trends direct crossnational comparisons In Taiwan prior implementation NHI pro gram hemophiliacs obtained factor concentrates relief disease progression arthropathies disabili ty complications After implementation 1995 NHI program guaranteed hemophiliacs obtain better treatment Numerous studies shown factor concentrates single greatest source costs hemophilia care3537 Liou et al38 reported factor concentrates accounted 965 expenditures Taiwan Increasing availability use factor centrates improved quality care people hemophilia Taiwan Unfortunately treatment guidelines patients hemophilia established Moreover analysis showed number hospitals providing hemophilia care services increased 32 hos pitals 2003 44 hospitals 2007 Contrary ex pectation earliest hemophilia treatment center HTC established 1984 Taiwan number HTCs hospitals providing comprehensive care services hemophiliacs remains small In addition mandatory NHI registry lacks data es sential clinical information including viral infection status HIV HCV immunization treatment strategy dose regimen significant complications inhibitors liver disease joint disease cause death maternal carrier sta tus An accurate simple complete registry ensures quality patient information continued im provement hemophilia treatment needed To improve registry suggest establishment revised registry committee representatives key groupspatients healthcare providers government repre sentativeswho offer different perspectives achieve accuracy simplicity completeness manda tory registry database A userfriendly internetbased patient registry created simplify data collection future This modeled existing successful internet based registries cancer organ transplan tation Department Health DOH Taiwan The registry operated DOH orga nize advisory board standardize terminology coding internet platform In addition ef fort increase participation hospitals physicians specialized nurses provide care services persons hemophilia providing data newly diagnosed indi viduals registry The Bureau Health Promotion promoted nationwide newborn screening services 1985 1997 end 2007 screening rates reported higher 995 Newborns diagnosed hemophilia referred treatment genetic counseling prevent sequelae A national registry dynamic tool hemophilia care continually updated order remain accurate useful There policies place en sure new data way registry setup work completed The registry critical planning evaluation healthcare programs Data appear year special bulletin annual reg istry report published Ministry Health Analyses observed trends need published annual reports medical journals The registry provides database future hemophilia research efforts Our study demonstrated ratios 125 1 24 1 78 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 Factor Usage Trends Hemophiliacs Taiwan HAHB HA HB 120 100 080 060 040 020 000 05 610 1115 1620 2125 2630 3135 3640 4145 4650 5155 5660 6165 6670 7175 7680 8185 8690 90 Fig 4 Agedistribution prevalence 100000 males December 31 2007 HA hemophilia A HB hemophilia B use FVIII FIX IUs capita recombinant centratestoplasmaderived concentrates respectively 2007 Accordingly differences clinical economic impact recombinant concentrates compared plasma derived concentrates particular risk hibitor development pharmacokinetic differences dosage regimens duration factor support focus attention future3945 The main limitation retrospective study passive nature NHI healthcare registry catastroph ic illness data obtained catastrophic illnesses This study performed based recent available claim data NHIRD However mandatory NHI pro gram insures 99 Taiwanese population geographic regions populations Taiwan au thor confident baseline epidemiologic profiles factor concentrate usage trends Taiwan represented Unfortunately assessment age distribution prevalence hemophiliacs shown Fig 4 prev alence relatively lower age group 010 years 1120 years likely reflected milder cases included similar prevalences obtained Asia countries including Japan Korea Singapore However previous studies shown median age 4 years diagnosis moderate patients 14 years patients mild HA Italian regis try19 EuropeanUS proportions Caucasian pa tients severe hemophilia lower gions globe survey46 The actual effect limitation results unknown In summary populationbased study mophilia date Taiwan This retrospective study fulfills gap epidemiology factor usage trend information hemophilia Taiwan provides useful data crossnational comparison The mandatory NHI healthcare registry hemophilia deserves continuous improvement A better designed patientcentered registry empower detailed information collection subsequent analysis ACKNOWLEDGEMENTS This study sponsored Hemophilia Care Re search Center TriService General Hospital Taipei Taiwan supported Baxter Education Fund REFERENCES 1 Fischer K Van Den Berg M Prophylaxis severe haemophilia clinical economical issues Haemophilia 2003937681 2 Mannucci PM Tuddenham EG The hemophiliasfrom royal genes gene therapy N Engl J Med 200134417739 3 Darby SC Kan SW Spooner RJ Giangrande PL Hill FG Hay CR et al Mortality rates life expectancy causes death people hemophilia A B United Kingdom infected HIV Blood 200711081525 4 Franchini M Tagliaferri A Mannucci PM The management hemophilia elderly patients Clin Interv Aging 200723618 5 Plug I Van Der Bom JG Peters M MauserBunschoten EP De GoedeBolder A Heijnen L et al Mortality causes death patients hemophilia 19922001 prospective cohort study J Thromb Haemost 200645106 6 Street A Hill K Sussex B Warner M Scully MF Haemophilia ageing Haemophilia 200612 Suppl 3812 7 Plug I Peters M MauserBunschoten EP GoedeBolder A Heijnen L Smit C et al Social participation patients mophilia Netherlands Blood 200811118115 8 Guidelines management hemophilia 2005 accessed 2012 Aug 8 Available httpwfhorg2docsPublicationsDi agnosis_and_TreatmentGuidelines_Mng_Hemophiliapdf 9 Cherishing health insurance healthy Taiwan 2006 accessed 2012 Aug 8 Available httpwwwnhigovtwResource webdataAttach_13792_2_cherishingpdf 10 National Health Insurance Taiwan 2011 Annual Report ac cessed 2012 Aug 8 Available httpwwwnhigovtwRe sourcewebdata13767_1_NHI20IN20TAIWAN20 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013 79 TsuChiang Tu et al 201120ANNUAL20REPORTpdf fidBFFEE6AB018CFAF8 11 Ahmad OB BoschiPinto C Lopez AD Murray CJ Lozano R Inoue M Age Standardization rates new WHO standard 2001 accessed 2010 Aug 8 Available httpwwwwhoint healthinfopaper31pdf 12 Population age accessed 2010 Aug 8 Available http sowfmoigovtwstatyeary0201xls 13 Causes death statistics accessed 2010 Aug 8 Available httpwwwdohgovtwCHT2006DisplayStatisticFileaspxd 73104s1 14 Stonebraker JS Brooker M Amand RE Farrugia A Srivastava A A study reported factor VIII use world Haemophilia 2010163346 15 StataCorp LP 4905 Lakeway Drive College Station Texas 77845 4512 USA 16 Stonebraker JS BoltonMaggs PH Soucie JM Walker I Brooker M A study variations reported haemophilia A prevalence world Haemophilia 2010162032 17 Ling SC Chan GCF Shing MMK Yuen HL Lee ACW Chan CW et al Children Adolescents Haemophilia Hong Kong Epidemiological Clinical Review HK J Paediatr 200611139 18 Plug I van der Bom JG Peters M MauserBunschoten EP Go edeBolder A Heijnen L et al Thirty years hemophilia treat ment Netherlands 19722001 Blood 20041043494500 19 Iorio A Oliovecchio E Morfini M Mannucci PM Association Italian Hemophilia Centres Directors Italian Registry Haemo philia Allied Disorders Objectives methodology data analysis Haemophilia 20081444453 20 Annual Report 2009 United Kingdom Haemophilia Centre Doc tors Organisation 2009 accessed 2010 Aug 8 Available httpwwwukhcdoorgdocsAnnualReports2009Annual20 Report20200920slidespdf 30 Statistics HIVAIDS 19842003131 accessed 2010 Aug 8 Available httpwww2cdcgovtwpublicData8121710212971 pdf 31 Statistics HIVAIDS 198420071231 accessed 2010 Aug 8 Available athttpwwwcdcgovtwenglishinfoaspxtreeid0 0ed75d6c887bb27nowtreeid1d256e6c8b243c1dtid1E0691 878D687950 32 Berntorp E Boulyjenkov V Brettler D Chandy M Jones P Lee C et al Modern treatment haemophilia Bull World Health Organ 199573691701 33 Ono O Suzuki Y Yosikawa K Wada I Doi Y Takano M et al Assessment haemophilia treatment practice pattern Japan Haemophilia 20091510328 34 Carcao MD Aledort LM Round Table Group Prophylaxis haemophilia populationoptimizing therapy Haemophilia 20071322732 35 Smith PS Teutsch SM Shaffer PA Rolka H Evatt B Episodic versus prophylactic infusions hemophilia A costeffective ness analysis J Pediatr 199612942431 36 Carlsson KS Höjgård S Lindgren A Lethagen S Schulman S Glomstein A et al Costs ondemand prophylactic treat ment severe haemophilia Norway Sweden Haemophil ia 20041051526 37 Heemstra HE Zwaan T Hemels M Feldman BM Blanchette V Kern M et al Cost severe haemophilia Toronto Haemophil ia 20051125460 38 Liou WS Tu TC Cheng SN Chou TY Lee CF Lin TK et al Secondary prophylaxis treatment versus ondemand treatment patients severe haemophilia A comparisons cost comes Taiwan Haemophilia 2011174554 39 Coppola A Franchini M Tagliaferri A Prophylaxis people haemophilia Thromb Haemost 200910167481 21 Canadian Hemophilia registryFactor VIII Hemophilia A 2009 accessed 2010 Aug 8 Available httpfhsmcmasterca chrpdf09CHRVIII090413pdf 40 Ettingshausen CE Kreuz W Recombinant vs plasmaderived products especially intact VWF inhibitor development Haemophilia 200612 Suppl 61026 22 Soucie JM Evatt B Jackson D Occurrence hemophilia United States The Hemophilia Surveillance System Project Inves tigators Am J Hematol 19985928894 23 Stonebraker JS BoltonMaggs PHB Soucie JM Walker I Brokker M A study variations reported hemophilia B prevalence world accessed 2011 Dec 10 Avail able httpwww1wfhorg2docsPublicationsStatisticsFF 10_Prevalence_HemophiliaBpdf 24 Canadian Hemophilia registryFactor IX Hemophilia B 2009 accessed 8 Aug 2010 Available httpfhsmcmasterca chrpdf09CHRIX090413pdf 25 Chan V Chan TK Liu VW Wong AC Restriction fragment length polymorphisms associated factor VIII C gene Chi nese Hum Genet 19887912831 26 Chen YC Hu SH Cheng SN Chao TY Genetic analysis hae mophilia A Taiwan Haemophilia 20101653844 27 Tagliaferri A Rivolta GF Iorio A Oliovecchio E Mancuso ME Morfini M et al Mortality causes death Italian persons haemophilia 19902007 Haemophilia 20101643746 28 MejiaCarvajal C Czapek EE Valentino LA Life expectancy hemophilia outcome J Thromb Haemost 200645079 29 Cases HIVAIDS exposure category accessed 2012 Aug 8 Available httpwwwcdcgovtwdownloadfileaspx 41 Wight J Paisley S The epidemiology inhibitors haemophilia A systematic review Haemophilia 2003941835 42 Goudemand J Rothschild C Demiguel V Vinciguerrat C Lambert T Chambost H et al Influence type factor VIII concen trate incidence factor VIII inhibitors previously treated patients severe hemophilia A Blood 20061074651 43 Gouw SC van der Bom JG Auerswald G Ettinghausen CE Tedgård U van den Berg HM Recombinant versus plasmade rived factor VIII products development inhibitors previously untreated patients severe hemophilia A CA NAL cohort study Blood 200710946937 44 Chalmers EA Brown SA Keeling D Liesner R Richards M Stirling D et al Early factor VIII exposure subsequent inhibi tor development children severe haemophilia A Haemo philia 20071314955 45 Coppola A Santoro C Tagliaferri A Franchini M DI Minno G Understanding inhibitor development haemophilia A clinical prediction prevention strategies Haemophilia 201016 Suppl 1139 46 Geraghty S Dunkley T Harrington C Lindvall K Maahs J Sek J Practice patterns haemophilia A therapy global progress wards optimal care Haemophilia 2006127581 80 Yonsei Med J httpwwweymjorg Volume 54 Number 1 January 2013